Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.49 USD | -0.55% |
|
-12.66% | -61.87% |
Jun. 04 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
1st Jan change | Capi. | |
---|---|---|
-61.87% | 1.79B | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024